Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

Executive Summary

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

You may also be interested in...



Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.

Merck Strengthening Vaccine Capabilities By Acquiring Troubled Immune Design

Recently battered by clinical setbacks, Immune Design has a co-development partnership with Merck around Keytruda and Merck’s Perlmutter is a former board member. Merck would pay roughly $300m to acquire the company and its immune system-boosting technologies.

Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel